Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of luspatercept versus placebo for transfusion-dependent anemia in myelofibrosis on JAK2 inhibitor therapy
MOH_2021-02-04_009718Phase 3Not yet recruiting
- Sponsor
- Celgene Corporation
- Start
- Jan 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myelophthisis comparing Reblozyl + best supportive care with Control: Placebo + best supportive care (2 arms). Planned start Jan 2021; status: not yet recruiting.
02
Drugs
luspatercept
03
Conditions
myelophthisis
Beyond the preview
Go deeper on MOH_2021-02-04_009718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-02-04_009718.